Semaglutide

At a glance

Overview

Semaglutide appears in Ozempic, Rybelsus and Wegovy, but these products have different evidence, indications and delivery systems. Current Wegovy labeling includes injectable and oral formulations for adult weight management and cardiovascular risk reduction in eligible patients; the injection also has pediatric obesity and selected MASH indications. Ozempic has diabetes, cardiovascular and kidney-outcome indications in defined adult populations. Oral absorption depends on the formulation, so tablet and injectable amounts are not interchangeable. This is a medicine for diagnosed conditions with ongoing follow-up, not evidence that semaglutide benefits every person seeking metabolic optimization.

Supporting sources [1] [2] [3] [4]

How it works

Semaglutide activates the glucagon-like peptide-1 receptor. It increases insulin secretion and lowers glucagon when glucose is elevated, influences appetite and food intake, and delays gastric emptying. Structural changes and albumin binding prolong exposure compared with the short-lived natural hormone. Appetite reduction contributes substantially to weight loss, while clinical trials establish specific cardiovascular and kidney benefits that cannot be inferred from weight change alone.

Supporting sources [1] [2] [3] [4]

Approved uses and product differences

Wegovy injection includes obesity treatment from age 12 and, in adults, noncirrhotic MASH with F2–F3 fibrosis under accelerated approval. Oral Wegovy has adult weight and cardiovascular indications. Ozempic’s current label includes adults with type 2 diabetes and chronic kidney disease.

Supporting sources [1] [2]

What the major trials show

STEP 1 established substantial weight reduction in adults without diabetes. SELECT demonstrated fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. These were different populations and endpoints; one result should not be substituted for another.

Supporting sources [3] [4]

Adverse effects and important exclusions

Nausea, vomiting, diarrhea and constipation are common. Labels address pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions and aspiration during anesthesia. Semaglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2; the thyroid warning originates in rodent findings.

Supporting sources [1] [2]

What follow-up considers

Diabetes treatment may require attention to hypoglycemia when insulin or insulin secretagogues are also used. Retinopathy history, kidney function during dehydration, gastrointestinal tolerance and pregnancy plans affect clinical management. Product switching requires a prescribing plan because exposure and indications differ.

Supporting sources [1] [2]

What accelerated MASH approval means

The MASH indication was supported by improvement in liver inflammation and fibrosis. Continued approval may depend on confirmation of clinical benefit. This does not establish reversal of cirrhosis or suitability for every cause of abnormal liver tests.

Supporting sources [1]

Common questions

Are Ozempic and Wegovy interchangeable? They contain the same active ingredient, but their approved indications, formulations and instructions differ. Product-specific information remains necessary.

Does a weight-management approval also establish every liver benefit? No. Wegovy's MASH indication concerns a defined noncirrhotic population and uses an accelerated approval pathway; it is not an approval for every fatty-liver condition.

Supporting sources [1] [2]